Pharmacological Management of Cancer-Related Pain

Donnelly S. , Walsh D. . The symptoms of advanced cancer. Semin Oncol. 1995; 22 (2 suppl 3): 67–72.

Foley K.M. . The relationship of pain and symptom management to patient requests for physician-assisted suicide. J Symptom Manage. 1991; 6(5): 289–297.

Mayer D.K. , Travers D. , Wyss A. . Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol. 2011; 29(19): 2683–2688.

Cherny N. . New strategies in opioid therapy for cancer pain. J Oncol Manage. 1999; 9(1): 8–15.

Stjernswärd J. . WHO cancer pain relief programme. Cancer Surv. 1987; 7(1): 195–208.

Bruera E. , Palmer J.L. , Bosnjak S. . Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004; 22(1): 185–192.

Fischer D.J. , Villines D. , Kim Y.O. . Anxiety, depression, and pain: differences by primary cancer. Support Care Cancer. 2010; 18(7): 801–810.

Gutgsell T. , Walsh D. , Zhukovsky D.S. . A prospective study of the pathophysiology and clinical characteristics of pain in a palliative medicine population. Am J Hosp Palliat Med. 2003; 20(2): 140–148.

Van den Beuken-van Everdingen M. , De Rijke J.M. , Kessels A.G. . Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007; 18(9): 1437–1449.

Green C.R. , Hart G. , Johnson T. . Cancer pain: an age-based analysis. Pain Med. 2010; 11(10): 1525–1536.

Cleary J.F. . The pharmacologic management of cancer pain. J Palliat Med. 2007; 10(6): 1369–1394.

Marcus D.A. . Epidemiology of cancer pain. Curr Pain Head Rep. 2011; 15(4): 231–234.

Davis M.P. , Walsh D. . Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Med. 2004; 21(2): 137–142.

Ventafridda V. , Tamburini M.A. , Caraceni A. . A validation study of the WHO method for cancer pain relief. Cancer. 1987; 59(4): 850–856.

Cancer Pain Guideline Panel; Agency for Health Care Policy and Research. Management of cancer pain: adults. Am Fam Physician. 1994; 49(8): 1853–1868.

Jadad A.R. , Browman G.P. . The WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluation. JAMA. 1995; 274(23): 1870–1873.

Smith H.S. . Potential analgesic mechanisms of acetaminophen. Pain Physician. 2009; 12(1): 269–280.

Larson A.M. , Polson J. , Fontana R.J. . Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005; 42(6): 1364–1372.

Julius D. , Basbaum A.I. . Molecular mechanisms of nociception. Nature. 2001; 413(6852): 203–210.

Malmberg A.B. , Yaksh T.L. . Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther. 1992; 263(1): 136–146.

Miranda H.F. , Silva E. , Pinardi G. . Synergy between the antinociceptive effects of morphine and NSAIDs. Can J Physiol Pharmacol. 2004; 82(5): 331–338.

Joishy S.K. , Walsh D. . The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome. J Pain Symptom Manage. 1998; 16(5): 334–339.

Reinhart D.J. . Minimising the adverse effects of ketorolac. Drug Safety. 2000; 22(6): 487–497.

Mercadante S. , Fulfaro F. , Casuccio A. . A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer. 2002; 38(10): 1358–1363.

Wood A.J. , Levy M.H. . Pharmacologic treatment of cancer pain. N Engl J Med. 1996; 335(15): 1124–1132.

Menelaou A. , Hutchinson M.R. , Quinn I. . Quantification of the O-and N-demethylated metabolites of hydrocodone and oxycodone in human liver microsomes using liquid chromatography with ultraviolet absorbance detection. J Chromatog B. 2003; 785(1): 81–88.

Prommer E. . Hydrocodone: does it have a role in palliative care? J Opioid Manage. 2009; 6(4): 295–299.

Rodriguez R.F. , Castillo J.M. , Castillo M.P. . Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial. Clin J Pain. 2008; 24(1): 1–4.

Rodriguez R.F. , Castillo J.M. , del Pilar Castillo M. . Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study. Clin Ther. 2007; 29(4): 581–587.

Leppert W. , Luczak J. The role of tramadol in cancer pain treatment—a review. Support Care Cancer. 2005; 13(1): 5–17.

Prommer E.E. . Tramadol: does it have a role in cancer pain management? J Opioid Manage. 2004; 1(3): 131–138.

Pedersen R.S. , Damkier P. , Brøsen K. . Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol. 2006; 62(7): 513–521.

Mejjad O. , Serrie A. , Ganry H. . Epidemiological data, efficacy and safety of a paracetamol-tramadol fixed combination in the treatment of moderate-to-severe pain. SALZA: a post-marketing study in general practice. Curr Med Res Opin. 2011; 27(5): 1013–1020.

Wilder-Smith C.H. , Schimke J. , Osterwalder B. . Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol. 1994; 5(2): 141–146.

Tawfik M.O. , Elborolossy K. , Nasr F. . Tramadol hydrochloride in the relief of cancer pain. A double blind comparison against sustained release morphine. Pain. 1990; 41: S377.

Bono A.V. , Cuffari S. . Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine [in French]. Drugs. 1996; 53(Suppl 2): 40–49.

Tzschentke T.M. , Christoph T. , Kogel B. . (-)-(1R, 2R)-3-(3-di-methylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323(1): 265–276.

Terlinden R. , Ossig J. , Fliegert F. . Absorption, metabolism, and excretion of14C-labeled Tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmaco. 2007; 32(3): 163–169.

Kneip C. , Terlinden R. , Beier H. . Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008; 2(1): 67–75.

Tapentadol (Nucynta)—a new analgesic [Erratum appears in Med Lett Drugs Ther. 2009; 51(1319): 68]. Med Lett Drugs Ther. 2015; 51(1318): 61–62.

Hatrick C. , Van Hove I. , Stegmann J.U. . Efficacy and tolerability of tapentadol immediate release and oxycodone HCL immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a ten-day, phase-3, randomized, double-blind-and placebo-controlled study. Clin Ther. 2009; 31: 260–271.

Kleinert R. , Lange C. , Steup A. . Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth Analg. 2008; 107(6): 2048–2055.

Oh C. , Rengelshausen J. , Mangold B. . A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. Int J Clin Pharmacol Ther. 2010; 48(10): 678–687.

Yue Q.Y. , Hasselstrom J. , Svensson J.O. . Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol. 1991; 31(6): 635–642.

Dean M. . Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004; 28(5): 497–504.

Dhaliwal H.S. , Sloan P. , Arkinstall W.W. . Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain. J Pain Symptom Manage. 1995; 10(8): 612–623.

World Health Organization. Cancer Pain Relief. 2nd ed. Geneva: World Health Organization; 2015.

Trescot A.M. , Datta S. , Lee M. . Opioid pharmacology. Pain Physician. 2008; 11 (2 suppl): S133–S153.

Somogyi A.A. , Barratt D.T. , Coller J.K. . Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007; 81(3): 429–444.

McQuay H. . Opioids in pain management. Lancet. 1999; 353(9171): 2229–2232.

Christrup L.L. . Morphine metabolites. Acta Anaesthesiol Scand. 1997; 41(1): 116–122.

de Wildt S.N. , Kearns G.L. , Leeder J.S. . Glucuronidation in humans. Clin Pharmaco. 1999; 36(6): 439–452.

Glare P.A. , Walsh T.D. . Clinical pharmacokinetics of morphine. Ther Drug Monitor. 1991; 13(1): 1–23.

Cherny N.I. . Opioid analgesics. Drugs. 1996; 51(5): 713–737.

Miners J.O. , Lillywhite K.J. , Birkett D.J. . In vitro evidence for the involvement of at least two forms of human liver UDP-glucuronosyltransferase in morphine 3-glucuronidation. Biochem Pharmacol. 1988; 37(14): 2839–2845.

Owen H. , Plummer J. , Ilsley A. . Variable-dose patient-controlled analgesia. Anaesthesia. 1995; 50(10): 855–857.

Caraceni A. , Hanks G. , Kaasa S. . Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012; 13(2): e58–e68.

Lauretti G.R. , Oliveira G.M. , Pereira N.L. . Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer. 2003; 89(11): 2027–2030.

Prommer E.E. . Methadone for cancer pain. Palliat Care Res Treat. 2010; 4: 1–10.

Murtagh F.E. , Chai M.O. , Donohoe P. . The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother. 2007; 21(2): 5–16.

Shaiova L. , Berger A. , Blinderman C.D. . Consensus guideline on parenteral methadone use in pain and palliative care. Palliat Support Care. 2008; 6(02): 165–176.

Piguet V. , Desmeules J. , Ehret G. . QT interval prolongation in patients on methadone with concomitant drugs. J Clin Psychopharmacol. 2004; 24(4): 446–448.

Ventafridda V. , Ripamonti C. , Bianchi M. . A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage. 1986; 1(4): 203–207.

Mercadante S. , Casuccio A. , Agnello A. . Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol. 1998; 16(11): 3656–3661.

Murray A. , Hagen N.A. . Hydromorphone. J Pain Symptom Manage. 2005; 29 (5 suppl): S57–S66.

Nalamachu S.R. , Kutch M. , Hale M.E. . Safety and tolerability of once-daily OROS-hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies. J Pain Symptom Manage. 2012; 44(6): 852–865.

Vallner J.J. , Stewart J.T. , Kotzan J.A. . Pharmacokinetics and bio-availability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981; 21(4): 152–156.

Thwaites D. , McCann S. , Broderick P. . Hydromorphone neuroexcitation. J Palliat Med. 2004; 7(4): 545–550.

Paramanandam G. , Prommer E. , Schwenke D.C. . Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone. J Palliat Med. 2011; 14(9): 1029–1033.

Moriarty M. , McDonald C.J. , Miller A.J. . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. J Drug Assess. 1999; 2(1): 41–48.

Quigley C. . Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002; (1): CD003447.

Kalso E. , Vainio A. . Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 1990; 47(5): 639–646.

Tallgren M. , Olkkola K.T. , Seppälä T. ,. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther. 1997; 61(6): 655–661.

Bruera E. , Belzile M. , Pituskin E. . Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 1998; 16(10): 3222–3229.

Gallego A.O. , Baron M.G. , Arranz E.E. . Oxycodone: a pharmacological and clinical review. Clin Translat Oncol. 2007; 9(5): 298–307.

Davis M.P. , Walsh D. , Lagman R. . Controversies in pharmacotherapy of pain management. Lancet Oncol. 2005; 6(9): 696–704.

Sloan P. , Slatkin N. , Ahdieh H. . Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer. 2005; 13(1): 57–65.

Adams M.P. , Ahdieh H. . Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy. 2004; 24(4): 468–476.

Kirvela M. , Lindgren L. , Seppala T. . The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth. 1996; 8(1): 13–18.

Prommer E. . Oxymorphone: a review. Support Care Cancer. 2006; 14(2): 109–115.

Sloan P. , Slatkin N. , Ahdieh H. . Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer. 2005; 13(1): 57–65.

Prommer E. . The role of fentanyl in cancer-related pain. J Palliat Med. 2009; 12(10): 947–954.

Sathyan G. , Guo C. , Sivakumar K. . Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr Med Res Opin. 2005; 21(12): 1961–1968.

Labroo R.B. , Paine M.F. , Thummel K.E. . Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for inter-individual variability in disposition, efficacy, and drug interactions. Drug Metab Disposit. 1997; 25(9): 1072–1080.

Tawfik M.O. , Bryuzgin V. , Kourteva G. . Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin. 2004; 20(3): 259–267.

Ripamonti C. , Fagnoni E. , Campa T. . Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer. 2006; 14(5): 400–407.

Payne R. , Mathias S.D. , Pasta D.J. . Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol. 1998; 16(4): 1588–1593.

Clark A.J. , Ahmedzai S.H. , Allan L.G. . Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin. 2004; 20(9): 1419–1428.

Farrar J.T. , Cleary J. , Rauck R. . Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998; 90(8): 611–616.

Coluzzi P.H. , Schwartzberg L. , Conroy J.D. . Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001; 91(1): 123–130.

Zeppetella G. . An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage. 2000; 20(4): 253–258.

Soares L.G. , Martins M. , Uchoa R. . Intravenous fentanyl for cancer pain: a “fast titration” protocol for the emergency room. J Pain Symptom Manage. 2003; 26(3): 876–881.

De Conno F. , Ripamonti C. , Sbanotto A. . A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain. J Pain Symptom Manage. 1991; 6(7): 423–427.

Pergolizzi J. , Aloisi A.M. , Dahan A. . Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010; 10(5): 428–450.

Bullingham R.E. , McQuay H.J. , Moore A. . Buprenorphine kinetics. Clin Pharmacol Ther. 1980; 28(5): 667–672.

Kress H.G. . Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009; 13(3): 219–230.

Evans H.C. , Easthope S.E. . Transdermal buprenorphine. Drugs. 2003; 63(19): 1999–2010.

Davis M.P. . Buprenorphine in cancer pain. Support Care Cancer. 2005; 13(11): 878–887.

Picard N. , Cresteil T. , Djebli N. . In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Disposit. 2005; 33(5): 689–695.

Davis M.P. . Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012; 10(6): 209–219.

Wolff R.F. , Aune D. , Truyers C. . Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin. 2012; 28(5): 833–845.

Sorge J. , Sittl R. . Transdermal buprenorphine in the treatment of chronic pain: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004; 26(11): 1808–1820.

Likar R. , Lorenz V. , Korak-Leiter M. . Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, phase III, randomized, open-label, crossover comparison. Clin Ther. 2007; 29(8): 1591–1606.

Böhme K. , Likar R. . Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clinic. 2003; 15(2): 193–202.

Hanks G. , Chemy N.I. , Christakis N.A. . Oxford Textbook of Palliative Medicine. 4th ed. Oxford, UK: Oxford University Press; 2015.

Zhang A. , Xiong W. , Bidlack J.M. . 10-ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors. J Med Chem. 2004; 47(1): 165–174.

Stringer M. , Makin M.K. , Miles J. . d-morphine, but not l-morphine, has low micromolar affinity for the non-competitive N-methyl-D-aspartate site in rat forebrain. Possible clinical implications for the management of neuropathic pain. Neurosci Lett. 2000; 295(1): 21–24.

Prommer E. . Levorphanol: the forgotten opioid. Support Care Cancer. 2007; 15(3): 259–264.

Weinberg D.S. , Inturrisi C.E. , Reidenberg B. . Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther. 1988; 44(3): 335–342.

Dixon R. , Crews T. , Inturrisi C. . Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain. Res Comm Chem Pathol Pharmacol. 1983; 41(1): 3–17.

Rowbotham M.C. , Twilling L. , Davies P.S. . Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003; 348(13): 1223–1232.

Miguel R. . Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control. 2000; 7(2): 149–156.

Wong G.Y. , Schroeder D.R. , Carns P.E. . Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA. 2004; 291(9): 1092–1099.

Plancarte R. , Amescua C. , Patt R.B. . Superior hypogastric plexus block for pelvic cancer pain. Anesthesiology. 1990; 73(2): 236–239.

Whistler J.L. , Chuang Hh , Chu P. . Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron. 1999; 23(4): 737–746.

Cherny N. , Ripamonti C. , Pereira J. . Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001; 19(9): 2542–2554.

Finn A.K. , Whistler J.L. . Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron. 2001; 32(5): 829–839.

Portenoy R.K. , Foley K.M. , Inturrisi C.E. . The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain. 1990; 43(3): 273–286.

Mercadante S. . Opioid rotation for cancer pain. Cancer. 1999; 86(9): 1856–1866.

Mercadante S. , Arcuri E. , Tirelli W. . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Symptom Pain Manage. 2000; 20(4): 246–252.

Bruera E. , Kim H.N. . Cancer pain. JAMA. 2003; 290(18): 2476–2479.

Mercadante S. , Radbruch L. , Caraceni A. . Episodic (breakthrough) pain. Cancer. 2002; 94(3): 832–839.

Radbruch L. , Trottenberg P. , Elsner F. . Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project. Palliat Med. 2011; 25(5): 578–596.

Muijsers R.B. , Wagstaff A.J. . Transdermal fentanyl. Drugs. 2001; 61(15): 2289–2307.

Vasisht N. , Gever L.N. , Tagarro I. . Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate. Clin Drug Invest. 2009; 29(10): 647–654.

Thomas J.R. , von Gunten C.F. . Pain in terminally ill patients. CNS Drugs. 2003; 17(9): 621–631.

Collins S. , Faura C. , Moore R.A. . Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage. 1998; 16(6): 388–402.

Stuart-Harris R. , Joel S.P. , McDonald P. . The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol. 2000; 49(3): 207–214.

Klepstad P. , Kaasa S. , Skauge M. . Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand. 2000; 44(6): 656–664.

De Conno F. , Ripamonti C. , Fagnoni E. . The MERITO study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during ‘titration phase’ in patients with cancer pain. Palliat Med. 2008; 22(3): 214–221.

Gatti A. , Reale C. , Occhioni R. . Standard therapy with opioids in chronic pain management. Clin Drug Invest. 2009; 29(1): 17–23.

McCarberg B.H. , Barkin R.L. . Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001; 8(3): 181–186.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain. v2.2015. http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed October 2, 2015.

Radbruch L. , Loick G. , Schulzeck S. . Intravenous titration with morphine for severe cancer pain: report of 28 cases. Clin J Pain. 1999; 15(3): 173–178.

Knotkova H. , Fine P.G. , Portenoy R.K. . Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009; 38(3): 426–439.

Mercadante S. , Ferrera P. , Villari P. . Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage. 2009; 37(4): 632–641.

Pasternak G.W. . Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci. 2001; 22(2): 67–70.

Mystakidou K. , Befon S. , Liossi C. . Comparison of tropisetron and chlorpromazine combinations in the control of nausea and vomiting in patients with advanced cancer. J Pain Symptom Manage. 1998; 15(3): 176–184.

Peuckmann V. , Elsner F. , Krumm N. . Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev. 2010; (11): CD006788.

Webster L. , Andrews M. , Stoddard G. . Modafinil treatment of opioid-induced sedation. Pain Med. 2003; 4(2): 135–140.

Dworkin R.H. , Backonja M. , Rowbotham M.C. . Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003; 60(11): 1524–1534.

Lussier D. , Huskey A.G. , Portenoy R.K. . Adjuvant analgesics in cancer pain management. Oncologist. 2004; 9(5): 571–591.

Tiina T. . Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996; 64(2): 293–302.

Ehrnrooth E. , Grau C. , Zachariae R. . Randomized trial of opioids versus tricyclic antidepressants for radiation-induced mucositis pain in head and neck cancer. Acta Oncologica. 2001; 40(6): 745–750.

Kautio A.L. , Haanpää M. , Saarto T. . Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Symptom Manage. 2008; 35(1): 31–39.

Preskorn S.H. , Irwin H.A. . Toxicity of tricyclic antidepressants—kinetics, mechanism, intervention: a review. J Clin Psychiatry. 1982.

Sindrup S.H. , Gram L.F. , Brøsen K. . The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990; 42(2): 135–144.

Sindrup S.H. , Bach F.W. , Madsen C. . Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003; 60(8): 1284–1289.

Tasmuth T. , Härtel B. , Kalso E. . Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain. 2002; 6(1): 17–24.

Smith E.M. , Pang H. , Cirrincione C. ; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309(13): 1359–1367.

Semenchuk M.R. , Sherman S. , Davis B. . Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. 2001; 57(9): 1583–1588.

Smith P. , Bruera E. . Management of malignant ureteral obstruction in the palliative care setting. J Pain Symptom Manage. 1995; 10(6): 481–486.

Yennurajalingam S. , Frisbee-Hume S. , Palmer J.L. . Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013; 31(25): 3076–3082.

Heimdal K. , Hirschberg H. , Slettebø H. ,. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neuro-Oncology. 1992; 12(2): 141–144.

Sørensen S. , Helweg-Larsen S. , Mouridsen H. , Hansen H.H. . Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer. 1994; 30(1): 22–27.

Vecht C.J. , Hovestadt A. , Verbiest H. . Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology. 1994; 44(4): 675.

Loblaw D.A. , Wu J.S. , Kirkbride P. . Pain flare in patients with bone metastases after palliative radiotherapy—a nested randomized control trial. Support Care Cancer. 2007; 15(4): 451–455.

Jensen T.S. . Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002; 6(suppl A): 61–68.

Caraceni A. , Zecca E. , Bonezzi C. . Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004; 22(14): 2909–2917.

Sabers A. , Gram L. . Newer anticonvulsants. Drugs. 2000; 60(1): 23–33.

Yajnik S. , Singh G.P. , Singh G. . Phenytoin as a coanalgesic in cancer pain. J Pain Symptom Manage. 1992; 7(4): 209–213.

Dunteman E.D. . Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. J Pain Palliat Care Pharmacother. 2005; 19(1): 35–43.

Rao R.D. , Flynn P.J. , Sloan J.A. . Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy. Cancer. 2008; 112(12): 2802–2808.

Bruera E. , Ripamonti C. , Brenneis C. . A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage. 1992; 7(3): 138–140.

Sharma S. , Rajagopal M.R. , Palat G. . A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage. 2009; 37(1): 85–93.

Ripamonti C. , Bruera E. . Pain and symptom management in palliative care. Cancer Control. 1996; 3(3): 204–213.

Sloan P. , Basta M. , Storey P. . Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain. Anesthesia Analgesia. 1999; 89(3): 760.

Wallace M.S. , Magnuson S. , Ridgeway B. . Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study. Reg Anesth Pain Med. 2000; 25(5): 459–467.

Galer B.S. , Rowbotham M.C. , Perander J. . Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999; 80(3): 533–538.

Gammaitoni A.R. , Davis M.W. . Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother. 2002; 36(2): 236–240.

Parsons C.G. . NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001; 429(1): 71–78.

Mercadante S. , Arcuri E. , Tirelli W. . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage. 2000; 20(4): 246–252.

Sinner B. , Graf B.M. . Ketamine. Modern Anesthetics. 2008: 313–333.

Sikora K. , Advani S. , Koroltchouk V. . Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol. 1999; 10(4): 385–390.

Schmid R.L. , Sandler A.N. , Katz J. . Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain. 1999; 82(2): 111–125.

Okon T. . Ketamine: an introduction for a pain and palliative medicine physician. Pain Physician. 2007; 10(3): 493.

Hardy J. , Quinn S. , Fazekas B. . Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. 2012; 30(29): 3611–3617.

Johnson J.R. , Potts R. . Cannabis-based medicines in the treatment of cancer pain: a randomised, double-blind, parallel group, placebo controlled, comparative study of the efficacy, safety and tolerability of Sativex and Tetranabinex in patients with cancer-related pain. British Pain Society; March 8-11, 2005; Edinburgh, Scotland.

Johnson J.R. , Burnell-Nugent M. , Lossignol D. . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010; 39(2): 167–179.

Perez J. . Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc). 2006; 42(8): 495–503.

Schreiber S. , Getslev V. , Backer M.M. . The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav. 1999; 64(1): 75–80.

Khojainova N. , Santiago-Palma J. , Kornick C. . Olanzapine in the management of cancer pain. J Pain Symptom Manage. 2002; 23(4): 346–350.

Prommer E.E. . Toxicity of bisphosphonates. J Palliat Med. 2009; 12(11): 1061–1065.

Rosen L.S. , Gordon D. , Kaminski M. . Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2000; 7(5): 377–387.

Saad F. , Gleason D.M. , Murray R. . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19): 1458–1468.

Berenson J.R. , Lichtenstein A. , Porter L. . Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996; 334(8): 488–493.

Rosen L.S. , Gordon D. , Tchekmedyian S. ; Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial. J Clin Oncol. 2003; 21(16): 3150–3157.

Prommer E. . Palliative oncology denosumab. Am J Hospice Palliat Care. 2015; 32(5): 568–572.

Lewington V.J. , McEwan A.J. , Ackery D.M. . A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer Clin Oncol. 1991; 27(8): 954–958.

Penn R.D. , Paice J.A. , Kroin J.S. . Octreotide: a potent new non-opiate analgesic for intrathecal infusion. Pain. 1992; 49(1): 13–19.

Bernard S.A. , Bruera E. . Drug interactions in palliative care. J Clin Oncol. 2000; 18(8): 1780–1799.